Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease

被引：0
|
作者：
Yacoub, W. [1 ]
Williet, N. [2 ]
Pouillon, L. [1 ,3 ]
Di-Bernado, T. [2 ]
Bittencourt, M. De Carvalho [4 ]
Nancey, S. [5 ]
Lopez, A. [1 ]
Paul, S. [6 ]
Zallot, C. [1 ]
Roblin, X. [2 ]
Peyrin-Biroulet, L. [1 ]
机构：
[1] Nancy Univ Hosp, Dept Gastroenterol, Vandoeuvre Les Nancy, France
[2] St Etienne Univ Hosp, Dept Gastroenterol, St Etienne, France
[3] Imelda GI Clin Res Ctr, Dept Gastroenterol, Bonheiden, Belgium
[4] Nancy Univ Hosp, Dept Immunol, Nancy, France
[5] Lyon Sud Hosp, Dept Gastroenterol, Pierre Benite, France
[6] St Etienne Univ Hosp, Dept Immunol, St Etienne, France
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P454
引用
收藏
页码：S334 / S334
页数：1
相关论文
共 50 条
  • [1] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (07) : 906 - 912
  • [2] Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Di Mario, C.
    Papa, A.
    Gremese, E.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S398 - S398
  • [3] Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, Jurij
    Sever, Nejc
    Ferkolj, Ivan
    Stabuc, Borut
    Smrekar, Natasa
    Kurent, Tina
    Kozelj, Matic
    Novak, Gregor
    Compernolle, Griet
    Tops, Sophie
    Gils, Ann
    Drobne, David
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (06) : 741 - 749
  • [4] Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
    Guidi, Luisa
    Pugliese, Daniela
    Tonucci, Tommaso Panici
    Bertani, Lorenzo
    Costa, Francesco
    Privitera, Giuseppe
    Tolusso, Barbara
    Di Mario, Clara
    Albano, Eleonora
    Tapete, Gherardo
    Gremese, Elisa
    Papa, Alfredo
    Gasbarrini, Antonio
    Rapaccini, Gian Ludovico
    Armuzzi, Alessandro
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (09) : 1189 - 1197
  • [5] Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
    Levartovsky, Asaf
    Cohen, Ido
    Abitbol, Chaya Mushka
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Kopylov, Uri
    Ben-Horin, Shomron
    Ungar, Bella
    [J]. BIOMEDICINES, 2023, 11 (06)
  • [6] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [7] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [8] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [9] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    [J]. GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [10] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease
    Hanzel, J.
    Sever, N.
    Ferkolj, I.
    Stabuc, B.
    Smrekar, N.
    Kozelj, M.
    Novak, G.
    Gils, A.
    Drobne, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
12345